ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 856

Am80, a Retinoic Acid Receptor Agonist, Ameliorates Murine Vasculitisthrough the Suppression of Neutrophil Migration and Activation

Chie Miyabe1, Yoshishige Miyabe1, Noriko Miura2, Kei Takahashi3, Yuya Terashima4, Etsuko Toda4, Fumiko Honda5, Tomohiro Morio5, Naohito Ohno2, Jun-ichi Suzuki6, Mitsuaki Isobe7, Kouji Matsushima4, Ryoji Tsuboi8, Nobuyuki Miyasaka1 and Toshihiro Nanki9, 1Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, 2Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, Japan, 3Department of Pathology, Toho University Ohashi Medical Center, Tokyo, Japan, 4Department of Molecular Preventive Medicine, The University of Tokyo, Tokyo, Japan, 5Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan, 6Department of Advanced Clinical Science and Therapeutics, The University of Tokyo, Tokyo, Japan, 7Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan, 8Department of Dermatology, Tokyo Medical University, Tokyo, Japan, 9Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Animal models, neutrophils and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis: Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Vasculitis is characterized by leukocyte infiltration in the vessel walls with destructive damage to mural structures. Retinoids are compounds that bind to retinoic acid receptors (RARs)and have biological activities of vitamin A, including modulatory effects on cell proliferation and differentiation. Synthetic retinoid, Am80, is a specific ligand for RAR-α/β but not RAR-γand is characterized by higher stability, fewer potential adverse effects, and superior bioavailability compared with all-trans retinoic acid. Previously we showed that Am80 ameliorated murine collagen-induced arthritis and experimental autoimmunemyositis. In this study, we examined the therapeutic effects of Am80 on a murine model of vasculitis induced by Candida albicans water-soluble fraction (CAWS).

Methods: Vasculitis was induced in BALB/c mice by intraperitoneal injection of CAWS from day 1 for 5 days. Neutrophils were depleted by injection of anti-neutrophil serum. Am80 was administrated orally once dailyfrom day 1 for 5 weeks or from day 8 for 4 weeks. Vasculitis was histologically evaluated. Number of migrated cells of labeled-adaptively transfer cells was counted. Chemotaxis was analyzed using cell mobility analysis device. Production of reactive oxygen species (ROS) and phosphorylation of mitogen-activated protein kinases was measured by flow cytometry. Concentrations of elastase, CCL2 and IL-6 were measured by enzyme-linked immunosorbent assays.

Results: Administration of CAWS induced vasculitis in the coronary arteries and aortic root with abundant neutrophil infiltration. Depletion of neutrophils reduced CAWS-induced vasculitis. Treatment with Am80 from day 1 significantly attenuated the experimental vasculitis. In addition, administration of Am80 from day 8, after the onset of vasculitis, also ameliorated the vasculitis. Am80 inhibited migration of transferred neutrophils into the site of vasculitis. In vitro, Am80 suppressed N-formyl-methionyl-leucyl-phenylalanine (fMLP)-induced chemotaxis of human peripheral blood neutrophils. Am80 reduced ROS production by phorbol 12-myristate 13-acetate, Pam3CSK4 or lipopolysaccharide (LPS)-stimulated peripheral blood neutrophils. Elastase release by fMLP and cytochalasin B-stimulated neutrophils was inhibited by incubation with Am80. Am80 also inhibited phosphorylation of extracellular signal-regulated kinase 1/2 and p38 in neutrophils-stimulated with fMLP and LPS. Moreover, Am80 reduced CCL2 and IL-6 production from human umbilical vein endothelial cells-stimulated with TNF-α or IL-1β.

Conclusion: Am80 significantly suppressed CAWS-induced vasculitis presumably through inhibition of neutrophil migration and activation.


Disclosure:

C. Miyabe,
None;

Y. Miyabe,
None;

N. Miura,
None;

K. Takahashi,
None;

Y. Terashima,
None;

E. Toda,
None;

F. Honda,
None;

T. Morio,
None;

N. Ohno,
None;

J. I. Suzuki,
None;

M. Isobe,
None;

K. Matsushima,
None;

R. Tsuboi,
None;

N. Miyasaka,
None;

T. Nanki,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/am80-a-retinoic-acid-receptor-agonist-ameliorates-murine-vasculitisthrough-the-suppression-of-neutrophil-migration-and-activation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology